A New Pancreatic Cancer Drug Is Reaching Patients Before Approval and the Testing Rules Are Not What Many Assume

Daraxonrasib is reaching pancreatic cancer patients through expanded access, and the pivotal trial enrolled them regardless of RAS mutation status.

Have A Referral?